I would say that in this setting, I would differentiate between acute graft-versus-host disease and chronic graft-versus-host disease. We know that fecal microbiota transplants, they’re going to be there and probably commercially available rather soon. So I’m not going to say… what I’m saying is that this is not something new. It’s been already ongoing for some years...
I would say that in this setting, I would differentiate between acute graft-versus-host disease and chronic graft-versus-host disease. We know that fecal microbiota transplants, they’re going to be there and probably commercially available rather soon. So I’m not going to say… what I’m saying is that this is not something new. It’s been already ongoing for some years. So we have mature data that we don’t have it available yet if it’s not within the clinical trial setting. So I see it as a good option in the near future. And in terms of chronic graft-versus-host disease, I think it’s relatively different what happens in the context of European health system and other health systems like the United States. For instance, in the United States, they have several drugs approved for chronic graft-versus-host disease, whereas in Europe, we’re starting to have those drugs with on-label use approval. We have used these drugs as an off-label or compassionate use programs or as foreign medication, but we are eagerly awaiting to have them approved and being able to prescribe them at the same level that other countries in other regions of the world have. We need more mature data with these drugs. So I think that the near future will be towards seeing what’s going to be the data with those drugs. And there are, in chronic graft-versus-host disease, I think that there are, thankfully, there are several clinical options now. And this is a scenario that we didn’t have 10 years ago, if we look back 10 years ago. So I’m optimistic with that. And my personal view also is that we probably would need to tackle chronic graft-versus-host disease by combining therapies. And I’m aware that there are efforts right now on trying to combine several strategies and also looking forward to those data too.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
